Lee Jeongshim, Kim Tae Hyung, Kim Yeon-Sil, Kim Myungsoo, Park Jae Won, Kim Sung Hyun, Kim Hyun Ju, Lee Chang Geol
Department of Radiation Oncology, Inha University Hospital, Inha University College of Medicine, Incheon, Korea.
Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Korea.
Cancer Res Treat. 2020 Oct;52(4):1031-1040. doi: 10.4143/crt.2020.310. Epub 2020 Jul 7.
The benefits of reirradiation for head and neck cancer (HNC) have not been determined. This study evaluated the efficacy of reirradiation using intensity-modulated radiotherapy (IMRT) for recurrent or second primary HNC (RSPHNC) and identified subgroups for whom reirradiation for RSPHNC is beneficial.
A total of 118 patients from seven Korean institutions with RSPHNC who underwent IMRT-based reirradiation between 2006 and 2015 were evaluated through retrospective review of medical records. We assessed overall survival (OS) and local control (LC) within the radiotherapy (RT) field following IMRT-based reirradiation. Additionally, the OS curve according to the recursive partitioning analysis (RPA) suggested by the Multi-Institution Reirradiation (MIRI) Collaborative was determined.
At a median follow-up period of 18.5 months, OS at 2 years was 43.1%. In multivariate analysis, primary subsite, recurrent tumor size, interval between RT courses, and salvage surgery were associated with OS. With regard to the MIRI RPA model, the class I subgroup had a significantly higher OS than class II or III subgroups. LC at 2 years was 53.5%. Multivariate analyses revealed that both intervals between RT courses and salvage surgery were prognostic factors affecting LC. Grade 3 or more toxicity and grade 5 toxicity rates were 8.5% and 0.8%, respectively.
IMRT-based reirradiation was an effective therapeutic option for patients with RSPHNC, especially those with resectable tumors and a long interval between RT courses. Further, our patients' population validated the MIRI RPA classification by showing the difference of OS according to MIRI RPA class.
头颈部癌(HNC)再程放疗的获益尚未明确。本研究评估了调强放疗(IMRT)用于复发性或第二原发性头颈部癌(RSPHNC)再程放疗的疗效,并确定了能从RSPHNC再程放疗中获益的亚组。
通过回顾性病历审查,对2006年至2015年间在韩国7家机构接受基于IMRT的再程放疗的118例RSPHNC患者进行了评估。我们评估了基于IMRT的再程放疗后放疗(RT)野内的总生存期(OS)和局部控制率(LC)。此外,还根据多机构再程放疗(MIRI)协作组提出的递归划分分析(RPA)确定了OS曲线。
中位随访期为18.5个月,2年总生存率为43.1%。多因素分析显示,原发部位、复发肿瘤大小、放疗疗程间隔和挽救性手术与总生存期相关。在MIRI RPA模型中,I类亚组的总生存期显著高于II类或III类亚组。2年局部控制率为53.5%。多因素分析显示,放疗疗程间隔和挽救性手术均为影响局部控制率的预后因素。3级及以上毒性反应率和5级毒性反应率分别为8.5%和0.8%。
基于IMRT的再程放疗是RSPHNC患者的有效治疗选择,尤其是那些肿瘤可切除且放疗疗程间隔较长的患者。此外,我们的患者群体通过显示根据MIRI RPA分类的总生存期差异,验证了MIRI RPA分类。